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IMPORTANCE Within the surgical population admitted to intensive care units (ICUs), cancer is
a common condition. However, clinicians can be reluctant to admit patients with cancer to
ICUs owing to concerns about survival.
OBJECTIVE To compare the clinical characteristics and outcomes of surgical patients with and
without cancer who are admitted to ICUs.
DESIGN, SETTING, AND PARTICIPANTS An observational retrospective cohort study using ICU
audit records linked to hospitalization discharge summaries, cancer registrations, and death
records of all 16 general adult ICUs in theWest of Scotland was conducted. All 25 017 surgical
ICU admissions between January 1, 2000, and December 31, 2011, were included, and data
analysis was conducted during that time.
EXPOSURES Patients were dichotomized based on a diagnosis of a solid malignant tumor as
determined by its documentation in the Scottish Cancer Registry within the 2 years prior to
ICU admission.
MAIN OUTCOMES ANDMEASURES Intensive care unit patients with cancer were compared
with ICU patients without cancer in terms of patient characteristics (age, sex, severity of
illness, reason for admission, and organ support) and survival (ICU, hospital, 6 months,
and 4 years).
RESULTS Within the 25017 surgical ICU patients, 13 684 (54.7%) weremale, the median
(interquartile range [IQR]) age was 64 (50-74), and 5462 (21.8%) had an underlying solid
tumor diagnosis. Patients with cancer were older (median [IQR] age, 68 [60-76] vs 62
[45-74] years; P < .001) with a higher proportion of elective hospitalizations (60.5% vs
19.8%; P < .001), similar Acute Physiology and Chronic Health Evaluation II scores (median for
both, 17), but lower use of multiorgan support (57.9% vs 66.7%; P < .001). Intensive care unit
and hospital mortality were lower for the cancer group, at 12.2% (95% CI, 11.3%-13.1%) vs
16.8% (95% CI, 16.3%-17.4%) (P < .001) and 22.9% (95% CI, 21.8%-24.1%) vs 28.1%
(27.4%-28.7%) (P < .001). Patients with cancer had an adjusted odds ratio for hospital
mortality of 1.09 (95% CI, 1.00-1.19). By 6months, mortality in the cancer group was higher
than that in the noncancer group at 31.3% compared with 28.2% (P < .001). Four years after
ICU admission, mortality for those with and without cancer was 60.9% vs 39.7% (P < .001)
respectively.
CONCLUSIONS AND RELEVANCE Cancer is a common diagnosis among surgical ICU patients
and this study suggests that initial outcomes compare favorably with those of ICU patients
with other conditions. Consideration that a diagnosis of cancer should not preclude
admission to the ICU in patients with surgical disease is suggested.
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U p to 5% of patients with a solid malignant tumor areadmitted to an intensive careunit (ICU)within 2yearsof diagnosis, with most receiving organ support dur-
ing their stay.1Most of these patients are admitted froma sur-
gical specialty unit, often at the time of surgical intervention
for their cancer. As the incidence of cancer continues to rise,2
it seems likely that the number of patients with cancer who
are considered for intensive care will also increase. There is
someevidence thatdecisions toadmitpatientswithcancer are
influenced by assumptions about poor prognoses, with can-
cer being the second most common cause cited for ICU
refusal.3,4 As outcomes in patients with cancer continue to
improve, these assumptions may not be valid.5 A systematic
review illustrated that variations in ICUmortality among pa-
tients with cancer were largely attributable to differences
between studypopulations’ severity of illness, type of admis-
sion, performance status, and need for organ support rather
than the presence of cancer.6
A limitationofmanypreviouslypublishedstudieshasbeen
that they do not include a comparison group of patients
without cancer; thus, it is difficult to determine the effect of
cancerwithin the same ICU setting.7 Taccone et al8 described
the outcomes of all patients with cancer admitted to 198
European ICUs in2002andfoundthat survivalofpatientswith
solid tumors was similar to that of ICU patients without can-
cer.More recently, a series of articles byBos and colleagues9-11
detailed outcomes in general ICUs for patients with cancer in
the Netherlands. They found that, while unplanned surgical
ICUadmissionwasassociatedwith similar ICUmortality inpa-
tientswith andwithout cancer, in-hospitalmortality after ICU
admission was higher for surgical patients with cancer than
for those without cancer, at 17.4% compared with 14.6%.10
Considering the limited information on the comparative
outcomes of patients with and without cancer admitted to
general ICUs published to date, we sought to describe the
characteristics and outcomes of surgical patients with solid
malignant tumors following ICU admission.
Methods
Data Sources and Variables
This was a retrospective observational study of patients living
in theWest of Scotland region aged 16 years or olderwhowere
admitted to a general ICU located in the region between
January 1, 2000, and December 31, 2011. Within the United
Kingdom, ICU physicians have full admitting rights, although
the ICU and surgical team share patient care. Full details are
described elsewhere.1 Patients admitted from a surgical spe-
cialty at admission to the ICU were selected based on the ad-
mitting specialty recorded in the ICU database. Patients with
cancer were identified as having a diagnosis of a solid malig-
nant tumor on the Scottish Cancer Registry between January
1, 2000, and December 31, 2009.We compared these patients
with cancer and surgical patients admitted to the ICUbetween
January1,2000,andDecember31,2011,whodidnothaveapre-
cedingdiagnosisof cancerontheScottishCancerRegistry.Data
analysiswasconductedbetweenJanuary1,2000,andDecember
31, 2011, for ICUadmissionandJanuary 1, 2000, andDecember
31, 2009, for the Scottish Cancer Registry.
This study was approved by the West of Scotland
ResearchandEthicsCommittee.Approvals touse thedatawere
obtained from the West of Scotland Critical Care Research
Network, Scottish IntensiveCareSocietyAuditGroup, and the
West of Scotland Cancer SurveillanceUnit. Patient identifiers
weremadeavailable to the researchgroup, but the analysis for
this studywas performed on an anonymized data set. Ethical
reviewconcluded thatnoadditional patient consentwouldbe
required owing to the nature of the study.
The study used 4 linked data sets: the Scottish Cancer
Registry, Scottish Morbidity Record 01, national death
records, and the Scottish Intensive Care Society Audit Group
WardWatcher ICU database. WardWatcher collects data on
patient demographics, admitting specialty, admission diag-
nosis, the Acute Physiology and Chronic Health Evaluation
(APACHE) II scoring system,12 and type of organ support.
Organ support was defined as receipt of invasive mechanical
ventilation, vasoactive drugs to provide cardiovascular sup-
port, or renal replacement therapy.
All surgical patients in the ICU database were included in
the analysis.We used death and hospital discharge records to
identify whether patients died during their hospital stay.
Intensive care unit stays could not be matched to a hospital
discharge summary for649of25017patients (2.6%).For these
patients,hospitaldischargedateandstatuswere retrievedfrom
the WardWatcher data set. The nature of hospital admission
wasunknown for thesepatients and theywere excluded from
analysis of admission type (emergency vs elective).
APACHE II scores were not recorded for 5732 patients
(22.9%), andtheproportionofpatientswithmissingscoreswas
described for both groups. For calculation of the numbers of
organs supported, patients were categorized as not having
received support for an organ with missing data.
Statistical Analysis
Median and interquartile ranges (IQRs) were used to summa-
rize continuous variables, and Wilcoxon rank sum test was
applied to determine differences in median values. Pearson
χ2 test and exact 95% CIs were used to compare proportions.
Odds ratios (ORs) for hospital mortality were calculated for
the presence of cancer, age 65 years or older, emergency
hospitalization, direct admission from the surgical theater,
Key Points
Question Howdo features and outcomes vary for surgical patients
with andwithout cancer admitted to the intensive care unit?
Findings In this cohort study of 25017 surgical admissions to
general intensive care units in theWest of Scotland, cancer was a
commonmorbidity at 21.8% of all admissions. Intensive care unit
and hospital mortality were lower in the group of intensive care
unit patients with cancer; however, this survival advantage had
reversed by 6months.
Meaning Cancer is present in 1 in 5 intensive care unit surgical
admissions, and short-term survival for this group is favorable.
Characteristics and Outcomes of Patients With Solid Cancers Admitted to the Intensive Care Unit Original Investigation Research
jamasurgery.com (Reprinted) JAMA Surgery September 2018 Volume 153, Number 9 835
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a Glasgow University Library User  on 11/27/2018
reason for ICU admission, APACHE II score of 20 or higher
(higher scores indicate increased severity of illness and cor-
responding mortality), and year of group’s ICU admission. A
multivariate model was then constructed using factors with
significance at P < .05, determined using 2-tailed, paired
testing on univariate analysis with the exception of reason
for ICU admission documented as malignancy, because this
diagnosis had colinearity with the presence of cancer.
All patients were included in survival analysis. A time-
varying covariate indicated the period in ICU, the stay in the
hospital following discharge from the ICU, and the period fol-
lowing hospital discharge. Kaplan-Meier curves and log-rank
test were used to compare survival between the cancer and
noncancer group. Statistical analyses were performed using
Stata, version 14.0 (StataCorp).
Results
During the study period, there were 25017 surgical patients
admitted to general ICUs in the West of Scotland, of whom
13 694 (54.7%) were male. The median age was 64 years
(IQR, 50-74), and 5462 (21.8%) had an underlying solid
tumor diagnosis. Table 1 gives patient characteristics for
surgical admissions to ICU with and without a diagnosis
of cancer.
Table 1. Surgical Admissions to ICU in PatientsWith andWithout Cancera
Variable
All Patients Patients Who Received Organ Support
Noncancer
(n = 19 555)
Cancer
(n = 5462) P Value
Noncancer
(n = 13 046)
Cancer
(n = 3165) P Value
Men, No. (% [95% CI]) 10 696
(54.7 [54.0-55.4])
3201
(58.6 [57.3-59.9])
<.001 7312
(56.0 [55.2-56.9])
1941
(61.3 [59.6-63.0])
<.001
Median age (IQR), y 62 (45-74) 68 (60-76) <.001 63 (46-74) 68 (60-76) <.001
Emergency hospitalization,
No./total No. (% [95% CI])
15 255/18 979
(80.2 [79.6-80.8])
2128/5389
(39.5 [38.2-40.8])
<.001 10 892/12 680
(85.9 [85.3- 86.5])
1299/3128
(41.5 [39.8-43.3])
<.001
Admitted from surgical theater,
No. (% [95% CI])
12 026
(61.5 [60.8-62.2])
4375
(80.1 [79.1-81.2])
<.001 7436
(57.0 [56.2-57.9])
2329
(73.6 [72.1-75.2])
<.001
Reason for admission, No. (%)
Malignancy 244 (1.2) 2294 (42.0)
<.001
80 (0.6) 961 (30.4)
<.001
GI/liver 4778 (24.4) 1020 (18.7) 2624 (20.1) 555 (17.5)
Sepsis 3089 (15.8) 610 (11.2) 2949 (22.6) 540 (17.1)
Surgical complication 893 (4.6) 376 (6.9) 689 (5.3) 297 (9.4)
Respiratory disorder 1174 (6.0) 244 (4.5) 863 (6.6) 198 (6.3)
Hemorrhage 1377 (7.0) 206 (3.8) 992 (7.6) 168 (5.3)
Vascular 2392 (12.2) 56 (1.0) 1368 (10.5) 31 (1.0)
Trauma 1702 (8.7) 30 (0.6) 1103 (8.5) 18 (0.6)
Cardiovascular 769 (3.9) 180 (3.3) 393 (3.0) 99 (3.1)
Renal disorder 308 (1.6) 84 (1.5) 794 (6.1) 33 (1.0)
APACHE II score, median (IQR) 17 (12-22) 17 (13-21) .12 18 (14-24) 18 (14-23) .18
Not recorded, No. (%) 4073 (20.8) 1659 (30.4) <.001 1040 (8.0) 293 (9.3) .02
Respiratory support,
No./total No. (% [95% CI])
12 300/19 220
(64.0 [63.3-64.7])
2919/5306
(55.0 [53.7-56.4])
<.001 12 300
(94.3 [93.9-94.7])
2919
(92.2 [91.2-93.1])
<.001
Unknown, No. (%) 335 (1.7) 156 (2.9) <0.001 1 0 .62
Cardiovascular support,
No./total No. (% [95% CI])
7103/19 080
(37.2 [36.4 -37.9])
1584/5291
(29.9 [28.7-31.2])
<.001 7103
(54.4 [53.7-55.4])
1584
(50.0 [48.4-51.9])
<.001
Unknown, No. (%) 475 (2.4) 171 (3.1) .004 33 (0.3) 4 (0.1) .18
Renal support,
No./total No. (% [95% CI])
1557/16 882
(9.2 [8.8-9.7])
237/4674
(5.1 [4.5-5.7])
<.001 1557
(13.3 [12.7-14.0])
237
(8.3 [7.3-9.3])
<.001
Unknown, No. (%) 2673 (13.7) 788 (14.4) .15 1365 (10.5) 301 (9.5)
Organ support, No. (%)
0 6186 (31.6) 2146 (39.3)
<.001
0 0
<.001
1 6438 (32.9) 1779 (32.6) 6438 (49.3) 1779 (56.2)
2 5302 (27.1) 1197 (21.9) 5302 (40.6) 1197 (37.8)
3 1306 (6.7) 189 (3.5) 1306 (10.0) 189 (6.0)
Unknown for all modes 323 (1.7) 151 (2.8) <.001 0 0
ICU mortality,
No. (% [95% CI])
3295
(16.8 [16.3-17.4])
666
(12.2 [11.3-13.1])
<.001 3066
(23.5 [22.8-24.2])
588
(18.6 [17.2-19.9])
<.001
Hospital mortality,
No. (% [95% CI])
5490
(28.1 [27.4-28.7])
1252
(22.9 [21.8-24.1])
<.001 4693
(36.0 [35.1-36.8])
993
(31.4 [29.8-22.0])
<.001
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation (higher scores indicate increased severity of illness and correspondingmortality);
ICU, intensive care unit; IQR, interquartile range.
a Numbers are cumulative total.
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Intensive care unit patients with cancer tended to be older
thanpatientswithout cancerwithmedian (IQR) age 68 (60-76)
vs62(45-74)years(P < .001).Mostofthepopulationwithoutcan-
cer had been admitted to hospital as an emergency (15255 of
18979patients [80.2%]) incontrast toonly39.5%(2128of5389
patients)ofthepopulationwithcancer.AdmissiontoICUdirectly
fromthesurgical theaterwasmorecommoninthecancergroup
(80.1%[4375of5462patients]vs61.5%[12026of19555patients];
P < .001). Intensivecareunitadmissionwasrelatedtoanunder-
lyingsolidtumorfor2294(42.0%)ofthecancergroup.Themost
frequentdiagnosticgroupswereotherwisesimilarbetweenthe
cancerandnoncancergroupswithsepsis, gastrointestinal/ liver
diseaseandsurgicalcomplicationsascommoncausesforadmis-
sion. Vascular disease and traumaoccurredmore frequently in
the noncancer group.
The APACHE II score was available for 15 482 (79.2%) of
patientswithout cancerand3803 (69.6%)ofpatientswithcan-
cer with similar median (IQR) values for both groups (17 [12-
22] vs 17 [13-21]),P = .12).Organ supportwasprovided less fre-
quently in the cancer group compared with the noncancer
group (57.9%[3165of 5462patients] vs66.7%[13046of 19555
patients]; P < .001). Single-organ support did not differ be-
tween the two groups but the provision of multi-organ sup-
port was less for the cancer group (25.4% [1386 of 5462 pa-
tients] vs 33.8% [6608of 19 555patients];P < .001). Intensive
careunitandhospitalmortalitywere lower for thecancerpopu-
lationwith12.2%(666of5462patients)vs 16.8%(3295of 19555
patients) (P < .001) of patients dying in ICU, and 22.9% (1252
of 5462 patients) vs 28.1% (5490 of 19 555 patients) (P < .001)
dying in hospital.
ICU Patients Receiving Organ Support
There were 16 211 surgical patients admitted to the ICU who
received organ support during the study period (Table 1). Of
these, 3165 (19.5%) had a solid tumor diagnosis. The APACHE
II score was available for 92.0% of ICU patients without can-
cer (12006 of 13046) and 90.7% of ICU patients with cancer
(2872 of 3165), and themedian (IQR) valuewas 18 (14-24) and
18 (14-23). Within this group of patients, respiratory support
was the most common mode of support for both the cancer
and noncancer groups at 92.2% (2919 of 3165 patients) and
94.3% (12 300 of 13046 patients), respectively. Cardiovascu-
lar support was provided to 50.0% of the cancer group (1584
of 3165 patients) and 54.6% of the noncancer group (7103 of
13046patients). Data pertaining toprovisionof renal replace-
ment therapy was missing in 1365 patients without cancer
(10.5%) and 301 patients with cancer (9.5%). Renal replace-
ment therapywasnot commonlyprovided ineither group,but
those patients in the cancer group had a lower prevalence of
RRT (237 of 3165 patients [8.3%]) when compared with the
noncancer group (1557 of 13046 patients [13.3%]; P < .001).
Single-organ support was more common in the cancer group
(1779of3165patients [56.2%])with thenoncancergroup (6438
of 13046 patients [49.3%]).Mortalitywas lower in the cancer
group,with ICUmortality 18.6%(588of3165patients)vs23.5%
(3066of 13046patients),P < .001andhospitalmortality31.4%
(993 of 3165 patients) vs 36.0% (4693 of 13 065 patients),
P < .001.
Outcomes of Underlying Tumor Type
Table 2 lists all tumor types admitted to ICU during the
study period along with ICU and hospital mortality.
Short-term mortality varied considerably between different
cancer types.
Colorectal cancer was the commonest tumor type admit-
ted to ICU as a surgical admission with 2414 patients
(44.2%). Other common tumors included head and neck
(610 patients [11.2%]) and upper gastrointestinal tract (419
patients [7.7%] with stomach cancer and 355 patients [6.5%]
with esophageal cancer). Colorectal cancer had a high rate of
emergency hospitalization at 45.9% (1089 of 2372 patients)
with a correspondingly high median (IQR) APACHE II score
of 18 (14-22) compared with that seen in head and neck
tumors (median [IQR], 15 [12-19]) or esophageal cancer (me-
dian [IQR], 14 [11-19]). Organ support showed some variation
by underlying tumor type. Single-organ support was com-
mon in surgical patients with head and neck cancer (467 of
610 patients [76.6%]) compared with that seen in other com-
mon tumor types (553 of 2414 patients [22.9%]) with colo-
rectal cancer and 141 of 355 patients (39.7%) with esophageal
cancer. This difference was largely accounted for by the high
rate of mechanical ventilation, with 558 of 598 patients with
head and neck cancer (93.3%) receiving ventilation. There
was a high proportion of patients receiving no organ support
in the groups with colorectal cancer (1181 of 2414 patients,
48.9%) and stomach cancer (189 of 419 patients, 45.1%).
These groups also had a larger proportion of patients with
Table 2. Frequency of Tumor Types in the Surgical ICU Population
and Short-termMortality
Cancer Type
Surgical
ICU Cohort,
No. (%)
Mortality, % (95% CI)
ICU Hospital
Colorectal 2414 (44.2) 11.6 (10.3-12.9) 21.9 (20.2-23.6)
Head and neck 610 (11.2) 5.6 (3.9-7.7) 11.0 (8.6-13.7)
Stomach 419 (7.7) 10.7 (7.9-14.1) 22.0 (18.1-26.2)
Esophagus 355 (6.5) 8.5 (5.8-11.8) 17.7 (13.9-22.1)
Kidney 230 (4.2) 9.6 (6.1-14.1) 15.2 (10.8-20.5)
Lung 220 (4.0) 35.9 (29.6-42.6) 51.4 (44.6-58.1)
Bladder 172 (3.1) 7.0 (3.7-11.9) 26.7 (20.3-34.0)
Ovary 130 (2.4) 14.6 (9.0-21.9) 29.2 (21.6-37.8)
Prostate 102 (1.9) 8.8 (4.1-16.1) 21.6 (14.0-30.8)
Uterus 102 (1.9) 10.8 (5.5-18.5) 16.7 (10.0-25.3)
Breast 99 (1.8) 15.2 (8.7-23.8) 22.2 (14.5-31.7)
Pancreas 72 (1.3) 25.0 (15.5-36.6) 47.2 (35.3-59.3)
Liver 56 (1.0) 32.1 (20.3-46.0) 58.9 (45.0-71.9)
Small intestine 50 (0.9) 14.0 (5.8-26.7) 32.0 (19.5-26.7)
Thyroid 24 (0.4) 4.2 (1.1-21.1) 8.3 (1.0-27.0)
Testis 16 (0.3) 18.8 (4.0-45.6) 18.8 (4.0-45.6)
Mesothelioma 13 (0.2) 23.1 (5.0-53.8) 46.2 (19.2-74.9)
Melanoma 11 (0.2) 0 (0-28.5)a 18.2 (2.3-51.8)
Other 95 (1.7) 12.6 (6.7-21.0) 25.3 (16.9-35.2)
Unknown 82 (1.5) 39.0 (28.4-50.4) 68.3 (57.1-78.1)
Multiple 190 (3.5) 8.9 (5.3-13.9) 17.4 (12.3-23.5)
Total 5462 (100) 12.2 (11.3-13.1) 22.9 (21.8-24.1)
Abbreviation: ICU, intensive care unit.
a One-sided 97.5% CI.
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missing APACHE II scores (37.6% [908 of 2414 patients] and
29.8% [125 of 419 patients], respectively).
Factors AssociatedWith Hospital Mortality
Hospital mortality is described for different admission fea-
tures in patients with and without cancer in Table 3. Hospi-
tal mortality was lower in the cancer group when catego-
rized by the patient’s age, severity of illness, and admission
year. Mortality was higher in the cancer group for patients
admitted to the hospital electively (14.8%, 95% CI, 13.6%-
16.1%; vs 12.8%, 95% CI, 11.7%-13.9%; P = .01) and for
patients admitted to the hospital as an emergency (32.7%,
95% CI, 30.7%-34.7%; vs 29.1%, 95% CI, 28.4%-29.9%;
P = .001). Odds ratios are reported in Table 4 for factors
associated with hospital mortality. The factor with the
greatest association with hospital mortality was severity of
illness (APACHE II score, ≥20; OR, 4.67; 95% CI, 4.34-5.01)
followed by age 65 years or older (OR, 2.14; 95% CI, 2.01-
2.29) and emergency hospitalization (OR, 2.86; 95% CI,
2.62-3.12). Admission to the ICU directly from the surgical
theater was protective (OR, 0.53; 95% CI, 0.49-0.56).
Patients with cancer had an OR of 1.09 (95% CI, 1.00-1.19)
for hospital mortality after adjustment for age, hospitaliza-
tion type, admission source, sepsis, APACHE II score, and
year of ICU admission.
Longer-termMortality Following ICU Admission
Longer-term survival of surgical ICU patients with and with-
out cancer isdemonstrated in theFigure.While the initialmor-
tality associated with the critical illness appears similar, the
patients in thecancergrouphadahighermortalityby6months
(31.3%vs28.2%;P < .001). The survival curves continue todi-
vergeand,by4years, themortalityof surgical ICUpatientswith
cancer was 60.9% compared with 39.7% seen in the group
without cancer.
Discussion
In an unselected, population-based cohort, 1 in 5 surgical pa-
tientsadmitted to the ICUhadacancerdiagnosiswithin2years
of admission. These patientswith cancer appeared tohave an
initial survival advantage over the noncancer cohort with fa-
vorable ICU and hospital mortality rates. Compared with pa-
tientswithout cancer, thosewith cancerwere older andmore
likely to be admitted to the ICU following electivehospitaliza-
tion; however, they had similar severity of illness. This find-
ing is in keeping with those of previous studies.8,10
Malignancy was the commonest reason for ICU admis-
sion in the cancer group. In the noncancer cohort, 1.2% had
malignancy recorded for their admission diagnosis. It is pos-
sible that thiswas a diagnostic error inwhichmalignancywas
Table 3. Hospital Mortality in PatientsWith andWithout Cancer
by Admission Features
Variable
Patients, % (95% CI)
P Value
Noncancer
(n = 19 555)
Cancer
(n = 5462)
Age, y
<65 20.0 (19.1-20.6) 15.1 (13.6-16.8) <.001
≥65 37.8 (36.8-38.9) 27.6 (26.1-29.1) <.001
Hospitalization
Elective 12.8 (11.7-13.9) 14.8 (13.6-16.1) .01
Emergency 29.1 (28.4-29.9) 32.7 (30.7-34.7) .001
Admission from
Surgical theater 22.3 (21.5-23.0) 17.7 (16.6-18.9) <.001
Other 37.4 (36.3-38.5) 43.9 (40.9-46.9) <.001
Reason for admission
Malignancy 11.9 (8.1-16.6) 12.4 (11.1-13.8) .81
Sepsis 40.6 (38.9-42.4) 49.0 (45.0-53.1) <.001
Other 25.9 (25.2-26.6) 26.1 (24.4-27.9) .85
APACHE II
<20 15.4 (14.7-16.1) 14.1 (12.7-15.5) .10
≥20 54.2 (52.9-55.5) 28.5 (45.8-51.3) <.001
Unknown 23.2 (21.9-24.5) 15.6 (13.9-17.4) <.001
ICU admission year
2000-2003 31.9 (30.8-33.0) 23.3 (21.6-25.1) <.001
2004-2007 27.6 (26.5-28.6) 23.5 (21.8-25.3) <.001
2008-2011 24.4 (23.4-25.5) 20.5 (18.0-23.2) .009
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation
(higher scores indicate increased severity of illness and corresponding
mortality); ICU, intensive care unit.
Table 4. Multivariate Logistic Regression for Hospital Mortality
Variable
Univariate OR
(95% CI)
P
Value
Multivariate OR
(95% CI)
P
Value
Cancer 0.76 (0.71-0.82) <.001 1.09 (1.00-1.19) .048
Age, y
<65 1 [Reference] 1 [Reference]
≥65 2.28 (2.15-2.42) <.001 2.14 (2.01-2.29) <.001
Hospitalization
Elective 1 [Reference] 1 [Reference]
Emergency 2.66 (2.47-2.86) <.001 2.86 (2.62-3.12) <.001
Admit from
Surgical theater 0.43 (0.41-0.46) <.001 0.53 (0.49-0.56) <.001
Other 1 [Reference] 1 [Reference]
Reason for
admission
Malignancya 0.40 (0.36-0.46) <.001 NA
Sepsis 2.06 (1.91-2.22) <.001 1.42 (1.30-1.55) <.001
Other 1 [Reference] 1 [Reference]
APACHE II score
<20 1 [Reference] 1 [Reference]
≥20 6.35 (5.94-6.80) <.001 4.67 (4.34-5.01) <.001
Unknown 1.49 (1.38-1.61) <.001 1.46 (1.34-1.59) <.001
ICU admission year
2000-2003 1.35 (1.25-1.45) <.001 1.46 (1.34-1.58) <.001
2004-2007 1.15 (1.07-1.24) <.001 1.20 (1.10-1.31) <.001
2008-2011 1 [Reference] 1 [Reference]
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation
(higher scores indicate increased severity of illness and corresponding
mortality); ICU, intensive care unit; NA, not applicable; OR, odds ratio.
a Not included in multivariate model owing to colinearity with cancer.
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suspected prior to histologic confirmation. Alternatively, pa-
tientswithcancerwhowerenot residentsofScotlandmayhave
been treated inoneof the included ICUswithout appearingon
the Scottish Cancer Registry. Severity of illness scores for pa-
tientswithandwithoutcancerweresuggestiveofa similarbur-
den of acute illness. However, multiorgan support occurred
more frequently in the group of patientswithout cancer. This
difference could be due to treatment limitations imposed on
cancerpatientsor a lower frequencyofmultiorgan failure.The
cancer group had a higher proportion of patients without re-
cordedAPACHE II scores, whichmight reflect a “well” cohort
of patients admitted only for postoperative observation and
therefore excluded from scoring. When the group of patients
without organ support was excluded, analysis of patients ad-
mitted to the ICU for organ support revealed a similar pattern
of APACHE II scores between those with and without cancer,
but lower mortality in the cancer group.
In both groups, patients admitted to the hospital elec-
tively had a favorable mortality compared with those admit-
ted to the ICU after an emergency hospitalization. This find-
ing might be attributable to the opportunity for preoperative
optimization and selection of patientswithout significant co-
morbidity for intervention. When analyzed by emergency or
elective hospitalization type, mortality was higher for pa-
tientswith cancer comparedwith thenoncancer group.How-
ever, mortality for the elective admission cancer group was
lower than that in theemergencyadmissionnoncancer group.
We propose that the large proportion of elective hospitaliza-
tionswithin thecancergrouphasa significant associationwith
the apparent survival advantage of patients with cancer ad-
mitted to the ICU.
After multivariate regression analysis, patients with can-
cer had only amarginally increased risk (OR, 1.09) of hospital
mortality compared with the noncancer population. Factors
that had a greater association withmortality were severity of
illness, emergencyhospitalization, andolder age,whichall in-
creased the risk of hospital mortality, and admission directly
from the surgical theater, which reduced the risk. This find-
ing is consistentwithprevious studies that suggest that the im-
mediate critical illness has a greater influence on short-term
outcomes than the underlying cancer.6
Intensive care unit and hospital mortality varied consid-
erably by underlying cancer type consistent with that
described by Bos and colleagues.11 Favorable outcomes were
seen for patients with thyroid, head and neck, and kidney
tumors. In contrast, high ICU and hospital mortality rates
were observed in patients with pancreas, lung, and liver
cancer for which survival outside the ICU setting is gener-
ally poorer compared with other tumor types. Patients with
an unknown tumor type had the highest mortality rates
demonstrated, although this might reflect a group of
patients who died prior to definitive diagnosis or those for
whom further investigation would be inappropriate owing
to disease burden or severe comorbidities. While clinicians
should be aware that not all cancers are equal in terms of
survival following surgical ICU admission, mortality rates
are such that none of the tumor types should automatically
preclude admission.
Asmore patientswith cancer require critical care, clinical
judgment needs to be informedby knowledge of outcomes in
similar patients. The hospital mortality described for pa-
tients with cancer who are admitted to the ICU after elective
hospitalization in this study is significantly higher than that
described by Bos et al9 (14.8% vs 4.7%, respectively). How-
ever, the study by Bos et al only included patients who had a
planned admission to the ICU. In comparison, patients in the
present studymay have had a planned admission to the hos-
pital but required admission to the ICU only after an unex-
pectedcomplication. In thesamesetting, surgicalpatientswith
an unplanned admission to the ICU had a hospital mortality
of 17.4%,10which is nearly half of that described in this study.
This low mortality may be explained by the lower use of or-
gan support in the study by Bos et al and the inclusion of pa-
tients undergoing elective surgery but admitted as an emer-
gency after a complication. These differences highlight the
importance of reporting a comparator groupwithin the same
study population to allow any real differences to be appreci-
ated.
While immediate outcomes in this study may favor the
group with cancer, this advantage was reversed by 6 months
andsurvival thereafterwaspoorer in thegroupofpatientswith
anunderlying tumor.By4years, thedifference in survivalwas
39.1%comparedwith60.3%for surgical ICUpatientswith and
without cancer. To our knowledge, no previous study has de-
scribed longer-termsurvival for ICUpatientswith cancer com-
paredwith thosewithout cancer to this degree. It has beenes-
tablished in the literature that short-termoutcomesare related
to the critical illness rather than the underlying tumor,6 and
it seems likely that as patients recover from their critical ill-
ness, comorbidities such as cancer have an increasing asso-
ciation with survival in the longer term.
Strengths and Limitations
A strength of this study is that it presents the characteristics
of patientswith cancer admitted to nonspecialized ICUs from
Figure. Survival Analysis of PatientsWith andWithout Cancer
Following Surgical Intensive Care Unit Admission
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Therewas a statistically significant difference in survival by log-rank test (P < .001).
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asurgicalpopulation.The typeofcancerwasverified fromcan-
cer registration data. Our findings therefore are representa-
tive of practice in general hospitals and suitable for general-
ization.However, it isprobable thatAPACHEII scoresandorgan
support that were not recorded are not missing at random13
andmightdependon the severityof illness, theadmitting ICU,
andwhether the patient died during the ICU stay. Odds ratios
demonstrated a slight increase in hospital mortality in pa-
tientswithout anAPACHE II score recorded (OR, 1.46) and the
reason for this is unknown. This group of patients with unre-
cordedAPACHE II scores is likely tobeamixof thosewhowere
excluded fromscoringbecauseof ahigh-dependencyunit ad-
mission (in which survival would be expected to be favor-
able) and thosewhodiedbefore full scoringwaspossible.Ow-
ing to the retrospective design of this study, we do not know
the exact reason for this finding. A further limitation of this
study is that our analysiswas restricted to the information al-
readycollectedandwewere thereforeunable to report on spe-
cifics, suchasperformancestatusor tumorstage,bothofwhich
are known to have a significant association with survival.
Conclusions
We found that cancer is a common condition present in sur-
gical patients admitted to the ICU. Patients with cancer were
more likely tohavebeenadmitted to thehospital electivelyand
receive no organ support in the ICU. Short-term outcomes in
patients with cancer admitted to the ICU varied significantly
by underlying tumor type, severity of illness, and admission
features. Contrary to previous studies, ICUpatientswith can-
cerhad favorable short-termoutcomescomparedwith ICUpa-
tients without cancer, although this survival advantage had
disappeared by 6 months. After adjusting for other prognos-
tic variables, ICU patients with cancer did not have a mean-
ingful increase in their riskofhospitalmortalitycomparedwith
patientswithout cancer. In view of these findings a diagnosis
of cancer should not preclude admission to an ICU in surgical
patients. To be able to better informadmissiondecisions, fur-
therwork is neededon individual cancers todeterminewhich
features have prognostic value.
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